🚀 VC round data is live in beta, check it out!
Werewolf Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Werewolf Therapeutics and similar public comparables like Karolinska Development, RenovoRx, Passage Bio, AN2 Therapeutics and more.
Werewolf Therapeutics Overview
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Founded
2017
HQ
Employees
46
Website
Sectors
Financials (LTM)
EV
$868K
Werewolf Therapeutics Financials
Werewolf Therapeutics reported last 12-month revenue of — and negative EBITDA of ($65M).
In the same LTM period, Werewolf Therapeutics generated ($65M) in EBITDA losses and had net loss of ($68M).
Revenue (LTM)
Werewolf Therapeutics P&L
In the most recent fiscal year, Werewolf Therapeutics reported revenue of $2M and EBITDA of ($64M).
Werewolf Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA | ($65M) | XXX | ($64M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3336%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (3833%) | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($71M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (3673%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Werewolf Therapeutics Stock Performance
Werewolf Therapeutics has current market cap of $29M, and enterprise value of $868K.
Market Cap Evolution
Werewolf Therapeutics' stock price is $0.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $868K | $29M | 0.0% | XXX | XXX | XXX | $-1.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWerewolf Therapeutics Valuation Multiples
Werewolf Therapeutics trades at 0.5x EV/Revenue multiple, and 0.0x EV/EBITDA.
EV / Revenue (LTM)
Werewolf Therapeutics Financial Valuation Multiples
As of March 18, 2026, Werewolf Therapeutics has market cap of $29M and EV of $868K.
Equity research analysts estimate Werewolf Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Werewolf Therapeutics has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $868K | XXX | $868K | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Werewolf Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Werewolf Therapeutics Margins & Growth Rates
Werewolf Therapeutics' revenue in the last fiscal year declined by (100%).
Werewolf Therapeutics' revenue per employee in the last FY averaged $0.0M.
Werewolf Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3336%) | XXX | XXX | XXX |
| EBITDA Growth | (2%) | XXX | 3% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 992% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2939% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3931% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Werewolf Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Karolinska Development | XXX | XXX | XXX | XXX | XXX | XXX |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Passage Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| AN2 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Werewolf Therapeutics M&A Activity
Werewolf Therapeutics acquired XXX companies to date.
Last acquisition by Werewolf Therapeutics was on XXXXXXXX, XXXXX. Werewolf Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Werewolf Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWerewolf Therapeutics Investment Activity
Werewolf Therapeutics invested in XXX companies to date.
Werewolf Therapeutics made its latest investment on XXXXXXXX, XXXXX. Werewolf Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Werewolf Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Werewolf Therapeutics
| When was Werewolf Therapeutics founded? | Werewolf Therapeutics was founded in 2017. |
| Where is Werewolf Therapeutics headquartered? | Werewolf Therapeutics is headquartered in United States. |
| How many employees does Werewolf Therapeutics have? | As of today, Werewolf Therapeutics has over 46 employees. |
| Who is the CEO of Werewolf Therapeutics? | Werewolf Therapeutics' CEO is Daniel J. Hicklin. |
| Is Werewolf Therapeutics publicly listed? | Yes, Werewolf Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Werewolf Therapeutics? | Werewolf Therapeutics trades under HOWL ticker. |
| When did Werewolf Therapeutics go public? | Werewolf Therapeutics went public in 2021. |
| Who are competitors of Werewolf Therapeutics? | Werewolf Therapeutics main competitors are Karolinska Development, RenovoRx, Passage Bio, AN2 Therapeutics. |
| What is the current market cap of Werewolf Therapeutics? | Werewolf Therapeutics' current market cap is $29M. |
| What is the current revenue growth of Werewolf Therapeutics? | Werewolf Therapeutics revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Werewolf Therapeutics? | Current revenue multiple of Werewolf Therapeutics is 0.5x. |
| Is Werewolf Therapeutics profitable? | No, Werewolf Therapeutics is not profitable. |
| What is the current EBITDA of Werewolf Therapeutics? | Werewolf Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Werewolf Therapeutics? | Current EBITDA multiple of Werewolf Therapeutics is 0.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.